Squarepoint
VRTX icon

Squarepoint’s Vertex Pharmaceuticals VRTX Stock Holding History

Squarepoint’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.44M Sell
7,700
-9,100
-54% -$4.24M ﹤0.01% 1781
2025
Q4 		$7.62M Sell
16,800
-12,800
-43% -$5.52M 0.01% 1215
2025
Q3 		$11.6M Buy
29,600
+16,200
+121% +$6.77M 0.01% 1001
2025
Q2 		$5.97M Buy
13,400
+5,900
+79% +$2.72M 0.01% 1346
2025
Q1 		$3.64M Sell
7,500
-8,300
-53% -$3.87M ﹤0.01% 1635
2024
Q4 		$6.36M Buy
15,800
+3,300
+26% +$1.53M 0.01% 1454
2024
Q3 		$5.81M Buy
12,500
+2,900
+30% +$1.39M 0.01% 1315
2024
Q2 		$4.5M Buy
9,600
+1,700
+22% +$738K 0.01% 1449
2024
Q1 		$3.3M Sell
7,900
-1,700
-18% -$719K 0.01% 1760
2023
Q4 		$3.91M Buy
9,600
+7,900
+465% +$2.92M 0.01% 1549
2023
Q3 		$591K Buy
1,700
+300
+21% +$105K ﹤0.01% 2667
2023
Q2 		$493K Buy
1,400
+700
+100% +$236K ﹤0.01% 2627
2023
Q1 		$221K Buy
+700
New +$210K ﹤0.01% 2749
2022
Q3 		– Sell
-5,700
Closed -$1.61M – 3487
2022
Q2 		$1.61M Buy
+5,700
New +$1.53M 0.01% 1328

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Squarepoint's VRTX Position: Q1 2026 in Review

Squarepoint reduced its Vertex Pharmaceuticals (VRTX) stake by 98% in Q1 2026, selling an estimated $178M and leaving 6,752 shares worth $3.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1890.

Squarepoint first reported a position in VRTX in Q2 2015 and has held it in 36 quarters since. The position peaked at $238M in Q3 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Squarepoint held 6,752 shares of Vertex Pharmaceuticals worth $3.02M as of Q1 2026.
  • Squarepoint sold 382,268 Vertex Pharmaceuticals shares in Q1 2026, an estimated $178M.
  • Vertex Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1890 holding.
  • Squarepoint first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 36 quarters since.
  • Squarepoint's Vertex Pharmaceuticals position peaked at $238M in Q3 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.